Market Newsdesk

WINCHESTER, Virginia and BOISE, Idaho, Nov 12, 2020, Nov. 12, 2020 (GLOBE NEWSWIRE) — Trex Company (NYSE: TREX) and Albertsons Companies (NYSE: ACI) are elevating their shared commitment to sustainability with a special recycling effort to divert plastic waste from landfills.

 Albertsons Cos., which operates nearly 1,700 pharmacies, has collected more than 54,000 pounds of bulk medication dispensing bottles, the contents of which are used to fill individual prescriptions. Trex then recycles the plastic bottles to produce its industry-leading wood-alternative, environmentally friendly composite decking. The new effort expands upon a decades-long partnership in which Albertsons Cos. has contributed more than 200 million pounds of recycled plastic film – the equivalent of more than 5,000 truckloads — to the NexTrex^® plastic film recycling program for retailers and consumers.

 Such innovative programs bolster the circular economy that is supported and celebrated on America Recycles Day, November 15.

“Our associates throughout our stores and pharmacies have championed this effort and are excited that these plastic bottles will have a second life,” said Erin Shaal, Senior Director of Pharmacy Procurement. “Pharmacists and Pharmacy Associates at participating locations are meticulously prepping the bottles for recycling. We’re very thankful for this level of dedication and excited to play a role in our company’s broader commitment to reduce, reuse and recycle plastic.”

The Trex medication bottle recycling program launched at ACME pharmacies along the East Coast, Albertsons, Vons and Pavilions pharmacies in Southern California, and Albertsons and Safeway pharmacies in Oregon and Southern Washington. Jewel-Osco pharmacies in the Chicago area also participate in medication bottle recycling.

“NexTrex is an integral component to Trex’s sourcing efforts and Albertsons Cos. is one of our original and most dedicated retail partners,” said Dave Heglas, Senior Director, Supply Chain Excellence for Trex Company. “They aren’t content with simply participating. Rather, they advance their commitment and find new ways to make a difference.”

The Transformation

The plastic that Albertsons Cos. recycles through the NexTrex program is shipped to Trex’s manufacturing facilities in Winchester, Va., and Fernley, Nev. Each year, Trex uses approximately 400 million pounds of recycled plastic film – including more than 1.5 billion plastic bags – in the making of its world-famous decking, which is comprised of 95% recycled content.

While the new recycling program is exclusively for bulk pharmacy-use bottles, Albertsons Cos. and Trex have offered consumers a convenient way to recycle plastic bags and wraps at stores for many years. In-store recycling is more important than ever as recycling in America becomes increasingly difficult due to changes in what is accepted by curbside recycling programs. The entire Albertsons Cos. family of more than 20 well-known banners participates in the program, with the majority of stores serving as drop-off locations for customers. Customers can check the bin at their local store or review this list of accepted materials to learn what can be put in the in-store bins. (Please consult local stores directly for participation and COVID-19 restriction information.)

The NexTrex program offers an easy-to-execute, end-use solution for recycling plastic bags and wraps. The program is available through approximately 32,000 stores across the United States and Canada, including major national chains as well as regional and specialty retailers. Trex provides retail participants with instructional videos, promotional materials, and a list of qualifying recyclable materials, which include everyday plastic items such as grocery and retail bags, bread bags, case overwraps, and more.

For more information about the NexTrex program and a directory of participating stores, please visit Trex.com/Recycling.

 

About Trex Company

Trex Company is the world’s largest manufacturer of high-performance wood-alternative decking and railing, with more than 25 years of product experience. Stocked in more than 6,700 retail locations worldwide, Trex outdoor living products offer a wide range of style options with fewer ongoing maintenance requirements than wood, as well as a truly environmentally responsible choice. For more information, visit trex.com. You also can follow Trex on Twitter (@Trex_Company), Instagram (@trexcompany), Pinterest (trexcompany), or Houzz (trex-company-inc), “like” Trex on Facebook (@TrexCompany), or view product and demonstration videos on the brand’s YouTube channel (TheTrexCo).

 

About Albertsons Companies

Locally great and nationally strong, Albertsons Companies (NYSE: ACI) is a leading food and drug retailer in the United States. The company operates stores across 34 states and the District of Columbia under 20 well-known banners including Albertsons, Safeway, Vons, Jewel-Osco, Shaw’s, Acme, Tom Thumb, Randalls, United Supermarkets, Pavilions, Star Market, Haggen and Carrs. The Company is committed to helping people across the country live better lives by making a meaningful difference, neighborhood by neighborhood. In 2019 alone, along with the Albertsons Companies Foundation, the Company gave $225 million in food and financial support. In 2020, the Company made a $53 million commitment to community hunger relief efforts and a $5 million commitment to organizations supporting social justice. These efforts have helped millions of people in the areas of hunger relief, education, cancer research and treatment, social justice and programs for people with disabilities and veterans’ outreach.

Attachments

• Medication Bottle Recycling (1)
• Trex Decking

Teena Massingill
Albertsons Companies
925-738-1387
[email protected]

Sara Tatay
L.C. Williams & Associates for Trex Company
312/565-3900 or 800/837-7123
[email protected]

Nicholas Heim
L.C. Williams & Associates
312/565-3900 or 800/837-7123
[email protected]

DAYTONA BEACH, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) — TopBuild Corp.(NYSE:BLD), a leading installer and distributor of insulation and building material products to the U.S. construction industry, announced that John Peterson, Chief Financial Officer, will participate in a live fireside chat at Stephens Annual Investment Conference on Tuesday, November 17, at 2:00 p.m. ET

The 45-minute presentation will be webcast. To listen to the live webcast select the link below or go to the Investor Relations section of TopBuild’s website at www.topbuild.com. A replay of the webcast will be available one hour after the presentation ends.

https://kvgo.com/stephens/topbuild-november-2020

About
TopBuil
d

TopBuild Corp., a Fortune 1000 Company headquartered in Daytona Beach, Florida, is a leading installer and distributor of insulation and building material products to the U.S. construction industry. We provide insulation and building material services nationwide through TruTeam^®, which has over 200 branches, and through Service Partners^® which distributes insulation and building material products from over 75 branches. We leverage our national footprint to gain economies of scale while capitalizing on our local market presence to forge strong relationships with our customers. To learn more about TopBuild please visit our website at www.topbuild.com.

Investor Relations and Media Contact

Tabitha Zane
[email protected]
386-763-8801

AUDUBON, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that Dr. Sheeraz Qureshi (Hospital for Special Surgery, New York, NY) and Dr. Paul Park (University of Michigan, Ann Arbor, MI) were the first surgeons to utilize the ExcelsiusGPS^® Interbody Solutions module. Dr. Qureshi performed a robotic navigated transforaminal lumbar interbody (TLIF) fusion and Dr. Park executed a robotic navigated single position lateral interbody fusion procedure, both using the ExcelsiusGPS^® robotic navigation system.

Enhanced utility and efficiency further define ExcelsiusGPS^® as the leader in spinal robotics. The system delivers best-in-class responsiveness through next generation software, advanced merging capabilities, and faster robotic arm movement. With the use of navigated instruments to target planned interbody trajectories and optimal port or retractor placement, ExcelsiusGPS^® Interbody Solutions seamlessly improves surgeon workflow. “I am very excited for the newest evolution of the ExcelsiusGPS^® platform,” said Dr. Sheeraz Qureshi. “This update provides advanced solutions for interbody placement using a robotic navigation platform that do not currently exist.”

ExcelsiusGPS^® Interbody Solutions is changing what computer-assisted surgery means for surgeons globally. Surgery with ExcelsiusGPS^® has evolved from planning and placing pedicle screws to helping surgeons perform robotic navigated TLIF and LLIF procedures from start to finish. Surgeons can now seamlessly navigate disc preparation, trialing, and interbody insertion through a rigid arm-mounted retractor. ExcelsiusGPS^® Interbody Solutions allows for fine-tuned interbody planning of implant size and position with exceptional 3D visibility. Visualizing the implant plan while navigating instruments and implants may help surgeons better achieve surgery goals and execute plans, level by level. As Dr. Paul Park remarked, “The advanced planning and ability of the robot to impact surgery beyond screw placement makes Interbody Solutions the next step forward in the evolution of robotic spinal surgery.”

Globus Medical’s ExcelsiusGPS^® is designed to enhance the safety, accuracy, and operating room efficiency of spinal surgery. Every day, this revolutionary platform is helping surgeons and hospitals globally provide the best possible treatment options for their patients. Now, the best-in-class robotic navigation system advancing spine surgery just got better with ExcelsiusGPS^® Interbody Solutions.

Visit www.globusmedical.com/interbodysolutions to learn more.

About Globus Medical, Inc.

Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:

Brian Kearns
Senior Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email: [email protected]
www.globusmedical.com

HOFFMAN ESTATES, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) — CDK Global, Inc. (NASDAQ:CDK) has declared a regular quarterly cash dividend of $0.15 per share payable on December 30, 2020 to shareholders of record at the close of business on December 1, 2020.

About CDK Global

With $2 billion in revenues, CDK Global (NASDAQ:CDK) is a leading global provider of integrated information technology solutions to the automotive retail and adjacent industries. Focused on enabling end-to-end automotive commerce, CDK Global provides solutions to dealers in more than 100 countries around the world, serving approximately 30,000 retail locations and most automotive manufacturers. CDK solutions automate and integrate all parts of the dealership and buying process, including the acquisition, sale, financing, insuring, parts supply, repair and maintenance of vehicles. Visit cdkglobal.com.

Contacts:

Investor Relations Contact: Julie Schlueter 847.485.4643 [email protected]

Media Contact: Roxanne Pipitone 847.485.4423 [email protected]

LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP),announced today that its CEO, Gil Beyen, will present an update at the Jefferies Virtual London Healthcare Conference at 12:00pm EST / 05:00pm GMT / 6:00pm CET on November 18, 2020.

A webcast of the event will be available on ERYTECH’s website at www.erytech.com/investors/webcast/

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable,
EnterNext
PEA-PME 150 and Next Biotech indexes.        

For more information, please visit

www.erytech.com
        

CONTACTS

ERYTECH                      Eric Soyer CFO & COO	LifeSci Advisors, LLC Investor Relations Corey Davis, Ph.D.	NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations
+33 4 78 74 44 38 [email protected]	+1 (212) 915 – 2577 [email protected]	+33 1 44 71 94 94 [email protected]

PDF available at: http://ml.globenewswire.com/Resource/Download/2f6d2e16-6591-4b5f-9d7b-d3324e3dde89

TORONTO, Nov. 12, 2020 (GLOBE NEWSWIRE) —

All per share figures disclosed below are stated on a diluted basis.

For the periods ended September 30	Three months					Nine months
($ in thousands, except per share amounts)		2020		2019			2020			2019
Net revenue	$	52,042	$	45,983		$	152,067		$	136,237
Operating earnings		12,108		12,105			36,348			35,871
Net gains (losses)		35,739		(1,274	)		(82,296	)		72,566
Net earnings (loss) attributable to shareholders		42,201		8,275			(43,681	)		92,333
EBITDA(1)	$	16,238	$	16,036		$	47,910		$	46,783
Adjusted cash flow from operations(1)		10,507		13,053			39,230			36,081
Per share:
Net earnings (loss) attributable to shareholders	$	1.56	$	0.31		$	(1.72	)	$	3.37
EBITDA(1)		0.60		0.59			1.78			1.72
Adjusted cash flow from operations(1)		0.39		0.48			1.46			0.33
As at				2020			2019
($ in millions, except per share amounts)			September 30			December 31			September 30
Assets under management			$	32,734		$	31,147		$	30,243
Assets under administration				20,755			20,248			19,040
Shareholders’ equity				632			683			654
Securities				552			682			664
Per share:
Shareholders’ equity(1)			$	23.25		$	25.01		$	23.93
Securities(1)				20.30			24.99			24.30

The Company is reporting Operating earnings of $12.1 million for the quarter ended September 30, 2020, substantially unchanged from the $12.1 million reported in the third quarter of 2019.

The Net revenue for the current quarter grew to $52.0 million, $6.0 million or 13% higher than the $46.0 million reported in the same quarter in the prior year. Excluding the revenue contributions of $2.0 million from Aurrea Signature Inc. (“Aurrea”), and Modern Advisor Canada Inc. (“Modern Advisor”), two businesses which were acquired subsequent to the third quarter of 2019, the growth in Net revenue was $3.0 million. This organic growth was largely driven by growth in Guardcap Investment Management (“GuardCap”), the UK investment management subsidiary and IDC Worldsource Insurance Network (“IDC WIN”), the life insurance managing general agency subsidiary.   

Expenses in the current quarter were $39.9 million, a $6.0 million increase from $33.9 million in the same quarter in the prior year. Included in the current quarter’s expenses are the expenses of Aurrea, Modern Advisor and those involved with the expansion of the Canadian Retail Asset Management team, which is focused on providing investment solutions for the Canadian retail market. The total expenses associated with these three businesses were $2.9 million in the current quarter.

The Company’s assets under management (“AUM”) reached $32.7 billion as at September 30, 2020, a 5% increase from $31.1 billion as at December 31, 2019, and an 8% increase from $30.2 billion as at September 30, 2019. The continued recovery in the global financial markets and the significant inflow of assets experienced by GuardCap drove the growth in AUM during the current quarter. The AUM managed by GuardCap has grown to $8.0 billion by the end of the current quarter from $4.0 billion at the end of 2019.

The Company’s assets under administration (“AUA”) were $20.8 billion as at September 30, 2020, compared to $20.2 billion at the end of 2019 and $19.0 billion as at September 30, 2019. Included as at September 30, 2020 were $0.5 billion of AUA provided by Aurrea.

The global financial markets experienced continued recoveries during the third quarter from the significant decline in the first quarter, resulting in Net gains of $35.7 million for the current quarter, compared to Net losses of $1.3 million in the same quarter in the prior year.

As a result of the Net gains and Operating earnings described above, the Company’s Net earnings attributable to shareholders in the current quarter were $42.2 million, compared to $8.3 million in the same quarter in 2019.  

EBITDA⁽¹⁾ for the current quarter was $16.2 million, compared to $16.0 million in the same period in the prior year. Adjusted cash flow from operations⁽¹⁾ for the current quarter was $10.5 million, compared to $13.1 million in the same quarter in the prior year. The lower Adjusted cash flow from operations was due to significant tax installments being paid in the current quarter, compared to the prior year.

The Company’s Shareholders’ equity as at September 30, 2020 was $632 million, or $23.25 per share⁽¹⁾, compared to $683 million, or $25.01 per share⁽¹⁾ as at December 31, 2019, and $654 million or $23.93 per share⁽¹⁾ as at September 30, 2019.

As the global equity markets continued to recover in the current quarter, the fair value of the Company’s Securities experienced a continued increase in fair value. However, the fair value of the Company’s Securities are less than the December 31, 2019 value due to the disposal of a portion of the holdings of the Bank of Montreal (“BMO”) shares in the first half of the year and the current share price of BMO remaining below December 31, 2019 value. The fair value of the Company’s Securities as at September 30, 2020 was $552 million, or $20.30 per share⁽¹⁾, compared to $682 million, or $24.99 per share⁽¹⁾ as at December 31, 2019 and $664 million or $24.30 per share⁽¹⁾ as at September 30, 2019.

The Board of Directors has declared a quarterly eligible dividend of $0.16 per share, payable on January 18, 2021, to shareholders of record on January 11, 2021.

The Company’s financial results for the past eight quarters are summarized in the following table. All per share figures are stated on a diluted basis.

	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020		Dec 31, 2019	Sep 30, 2019		Jun 30, 2019	Mar 31, 2019	Dec 31, 2018
As at ($ in millions)
Assets under management	$ 32,734	$31,196	$27,527		$31,147	$30,243		$30,088	$29,631	$26,962
Assets under administration	20,755	20,010	18,152		20,248	19,040		18,784	18,745	17,385
For the three months ended ($ in thousands)
Net revenue	$ 52,042	$50,124	$49,901		$49,865	$45,983		$45,963	$44,291	$44,300
Operating earnings	12,108	13,427	10,813		13,030	12,105		12,590	11,176	12,137
Net gains (losses)	35,739	43,254	(161,289	)	24,140	(1,274	)	7,957	65,883	(89,001	)
Net earnings (loss)	42,652	51,244	(134,911	)	31,808	8,952		17,601	68,099	(69,652	)
Net earnings (loss) attributable to shareholders	42,201	50,486	(136,368	)	30,787	8,275		16,838	67,220	(70,449	)
Net earnings (loss) attributable to shareholders:
Per Class A and Common share (in $)
Basic	$ 1.66	$1.99	$(5.35	)	$1.20	$0.32		$0.65	$2.57	$(2.63	)
Diluted	1.56	1.87	(5.35	)	1.13	0.31		0.62	2.43	(2.63	)
Dividends paid (in $)	$ 0.160	$0.160	$0.150		$0.150	$0.150		$0.150	$0.125	$0.125
As at
Shareholders’ equity ($ in thousands)	$ 631,863	$596,265	$562,821		$682,777	$653,983		$647,983	$656,167	$599,311
Per Class A and Common share (1)(in $)
Basic	$ 24.80	$23.50	$22.18		$26.73	$25.49		$25.26	$25.14	$22.85
Diluted	23.25	22.07	20.94		25.01	23.93		23.73	23.66	21.57
Total Class A and Common shares outstanding (shares in thousands)	27,758	27,758	27,758		27,839	27,956		27,956	28,405	28,405

Guardian Capital Group Limited is a diversified financial services company founded in 1962. The Company provides institutional and high net worth investment management services to clients; financial services to international investors; and services to financial advisors in its national mutual fund dealer, securities dealer, and life insurance managing general agency. Its Common and Class A shares are listed on The Toronto Stock Exchange.

For further information, contact:

Donald Yi	George Mavroudis
Chief Financial Officer	President and Chief Executive Officer
(416) 350-3136	(416) 364-8341

^(
1
) The Company’s management uses EBITDA, EBITDA per share, Adjusted cash flow from operations, Adjusted cash flow from operations per share, Shareholders’ equity per share and Securities per share to evaluate and assess the performance of its business. These measures do not have standardized measures under International Financial Reporting Standards (“IFRS”), and are therefore unlikely to be comparable to similar measures presented by other companies. However, management believes that most shareholders, creditors, other stakeholders and investment analysts prefer to include the use of these measures in analyzing the Company’s results. The Company defines EBITDA as net earnings before interest, income taxes, amortization, stock-based compensation, net gains or losses, less amounts attributable to non-controlling interests. The Company defines Adjusted cash flow from operations as net cash from operating activities, net of changes in non-cash working capital items and non-controlling interests. The most comparable IFRS measures are Net earnings, which were $42.7 million for the quarter ended September 30, 2020 (2019 – $9.0 million), and Net cash from operating activities, which was $22.4 million for the quarter ended September 30, 2020 (2019 – $22.7 million). The per share amounts for EBITDA, Adjusted cash flow from operations, Shareholders’ equity and Securities are calculated by dividing the amounts by diluted shares, which Is calculated in a manner similar to net earnings attributable to shareholders per share. More detailed descriptions of these non-IFRS measures are provided in the Company’s Management’s Discussions and Analysis, including a reconciliation of these measures to their most comparable IFRS measures.

BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 2020 Jefferies Virtual London Healthcare Conference as follows:

Date:	Wednesday, November 18, 2020
Time:	11:25 a.m. Eastern Time
Webcast:	https://wsw.com/webcast/jeff141/osmt/1873875

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.

About Osmotica
Pharmaceuticals plc

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex^® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.

Osmotica has operations in the United States, Argentina, and Hungary.

Investor and Media Relations for Osmotica Pharmaceuticals plc

Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]